# Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction

## Authors

- Kevan English ([ORCID](https://orcid.org/0009-0006-8893-5696)) — Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States
- Christine Uwibambe ([ORCID](https://orcid.org/0000-0000-0000-0000)) — Department of Internal Medicine, Jersey Shore University Medical Center, Neptune, New Jersey, United States

## Article information

- **Journal:** The Ulutas Medical Journal (Ulutas Med J), ISSN 2149-388X
- **Issue:** Volume 11, Issue 2 (2025), pages 22–24
- **Article type:** Short Communication
- **Published online:** 2025-06-19
- **DOI:** [10.5455/umj.20250429034140](https://doi.org/10.5455/umj.20250429034140)
- **Licence:** [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)
- **Article page:** https://www.ulutasmedicaljournal.com/?mno=254988
- **PDF:** https://www.ulutasmedicaljournal.com/pdf/254988.pdf

## Abstract

Obesity is a well-known risk factor for heart failure with preserved ejection fraction (HFpEF). Through recent clinical trials, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been shown to decrease mortality and improve symptoms in patients with obesity and HFpEF. Based on the new existing data, we suggest a change in clinical practice for physicians globally. Evidence now supports the initiation of GLP-1/GIP agonists in patients with obesity and HFpEF. This short communication reviews some of the most recent data on GLP-1/GIP agonists that support their clinical indications for patients with obesity and heart failure.

## Keywords

Heart failure with preserved ejection fraction; Obesity; Glucagon-like peptide-1 receptor agonists; Systemic inflammation; Glucose-dependent insulinotropic polypeptide

## How to cite

English K, Uwibambe C. Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction. Ulutas Med J. 2025;11(2):22-24. doi:10.5455/umj.20250429034140

## References

1. Aryee EK, Ozkan B, Ndumele CE. Heart Failure and Obesity: The Latest Pandemic. Prog Cardiovasc Dis. 2023; 78:43-48 https://doi.org/10.1016/j.pcad.2023.05.003
2. Benn M, Marott SCW, Tybjærg -Hansen A, Nordestgaard BG. Obesity increases heart failure incidence and mortality: observational and Mendelian randomization studies totalling over 1 million individuals. Cardiovasc Res. 2023; 118(18):3576-3585 https://doi.org/10.1093/cvr/cvab368
3. Miller WL, Sorimachi H, Grill DE, Fischer K, Borlaug BA. Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure. Eur J Heart Fail. 2021; 23(7):1097-1105 https://doi.org/10.1002/ejhf.2121
4. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection GLP-1 Agonists in Obesity and Heart Failure Kevan English and Christine Uwibambe Fraction and Obesity. N Engl J Med. 2025; 392(5):427- https://doi.org/10.1056/nejmoa2410027
5. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023; 389(12):1069-1084 https://doi.org/10.1056/nejmoa2306963
6. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024; 390(15):1394-1407 https://doi.org/10.1056/nejmoa2313917
7. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022; 21(1):169 https://doi.org/10.1186/s12933-022-01604-7
8. Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, Mann JFE, MacIsaac RJ, Kosiborod MN, Kamenov Z, Idorn T, Hansen MB, Hadjadj S, Bakris G, Baeres FMM, Mahaffey KW; FLOW Trial Committees and Investigators. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J Am Coll Cardiol. 2024; 84(17):1615-1628 https://doi.org/10.1016/j.jacc.2024.08.004
9. Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Verma S, Abildstrøm SZ, Nygaard Einfeldt M, Rasmussen S, Abhayaratna WP, Ahmed FZ, Ben-Gal T, Chopra V, Ito H, Merkely B, Núñez J, Senni M, van der Meer P, Wolf D, Petrie MC, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. J Am Coll Cardiol. 2024 Oct 22;84(17):1587-1602. doi: 10.1016/j.jacc.2024.08.021. Epub 2024 Aug 30. Erratum in: J Am Coll Cardiol. 2025; 85(9):967-968
10. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024; 15:1431292 https://doi.org/10.3389/fendo.2024.1431292
